Strattera (atomoxetine) is a medication that can help individuals with ADHD with concentration difficulties. This is particularly effective for individuals who take a combination of stimulants, including methylphenidate (Ritalin) and amphetamines. By inhibiting the reuptake of norepinephrine, Strattera helps to restore the balance of norepinephrine in the brain. This neurotransmitter plays a crucial role in attention, impulse control, and decision making. This medication is often prescribed for children and adolescents, as it is known for its efficacy in pediatric ADHD management. It is important for individuals considering Strattera to be aware of the potential side effects and any interactions with other medications they may be taking. Strattera can also interact with certain foods and supplements, so it is important to consult with a healthcare professional before starting Strattera. Additionally, Strattera is not suitable for children and adolescents because it can have serious side effects in young children and adolescents, such as anxiety, tremors, and impulsiveness. The use of Strattera should always be preceded by a proper diagnosis and treatment plan. In some cases, Strattera may be prescribed off-label for other uses.
The side effects experienced with Strattera are usually mild and temporary. However, some individuals may experience more serious side effects. Some individuals may experience:
If any of these side effects persist or worsen, it is important to seek medical attention promptly. In the event that any of these side effects persist or worsen, it is important to seek medical attention promptly.
Strattera can interact with many other medications, so it is important to inform your healthcare provider about all medications you are taking. Some of the medications that may be prescribed to treat ADHD include:
If any of these interactions are found to be severe, it is important to seek medical attention immediately. In the event that any of these interactions persist or worsen, it is important to seek medical attention promptly.
It is important for individuals considering Strattera to be aware of all medications they are taking. Some medications that may be prescribed to treat ADHD include:
It is important to inform your healthcare provider about all medications you are taking, including over-the-counter medications, vitamins, and supplements. They may be able to provide additional information on potential interactions with Strattera or other medications that may affect its effects.
Strattera is commonly used for the treatment of attention deficit hyperactivity disorder (ADHD) and attention deficit hyperactivity disorder (ADHD-AD). Strattera can also be used to treat the symptoms of ADHD by increasing the amount of norepinephrine in the brain.
Efficacy and safety of Strattera 25 mg capsule were evaluated in clinical trials with adults. In 12 trials, the patients were treated with Strattera 25 mg capsule twice daily for 2 weeks. The primary end point was change in total daily dose of Strattera, with a secondary end point of change in total daily dose of Strattera in the presence of treatment-naïve patients. Secondary end points were the change in total daily dose of Strattera in the presence of treatment-naïve patients, and change in total daily dose of Strattera in the presence of non-responders. Safety, tolerability, and efficacy of Strattera were evaluated in 12 patients with primary and recurrent non-cancerous indications. Safety was evaluated in 7 patients and 5 in 7 patients with non-cancerous indications. In the presence of treatment-naïve patients, the mean change in total daily dose was <0.15 mg/day (mean change from baseline in total daily dose, +/− 0.30 mg/day), and the mean change in total daily dose was <0.15 mg/day (mean change from baseline in total daily dose, +/− 0.20 mg/day) in patients receiving Strattera. In patients with non-cancerous indications, the mean change in total daily dose was <0.15 mg/day, and the mean change in total daily dose was <0.15 mg/day in patients with non-cancerous indications. Safety was evaluated in 6 patients and 4 patients with non-cancerous indications. The mean change in total daily dose was <0.15 mg/day in the presence of treatment-naïve patients, and change in total daily dose was <0.15 mg/day in patients with non-cancerous indications. Safety was evaluated in 9 patients with non-cancerous indications, and 9 patients with primary non-cancerous indications. The safety profile of the use of Strattera in non-cancerous indications was evaluated in 8 patients with non-cancerous indications. The safety profile of the use of Strattera in non-cancerous indications was evaluated in 4 patients with non-cancerous indications. The safety profile of the use of Strattera in non-cancerous indications was evaluated in 1 patient with non-cancerous indications. In the presence of treatment-naïve patients, the mean change in total daily dose was <0.15 mg/day (mean change from baseline in total daily dose, +/− 0.40 mg/day) and the mean change in total daily dose was <0.15 mg/day (mean change from baseline in total daily dose, +/− 0.20 mg/day). Safety was evaluated in 4 patients with non-cancerous indications and 4 patients with primary non-cancerous indications. The safety profile of the use of Strattera in non-cancerous indications was evaluated in 2 patients with non-cancerous indications. The safety profile of the use of Strattera in non-cancerous indications was evaluated in 3 patients with non-cancerous indications.
Atomoxetine is used to treat major depressive disorder and to reduce the risk of suicidal thoughts in children and adolescents over ten years of age.
Atomoxetine may also be used for purposes not listed in this medication guide.
Dosage and administration.Atomoxetine should not be taken more than once in a 24-hour period. It is not recommended to take this medication more often than prescribed by a doctor.
Patients should be informed about the possibility of taking this medication before the first day of their menstrual period.
The use of atomoxetine is contraindicated in pregnancy and lactation settings. The drug should not be given to a woman who has previously had a heart attack, stroke, or mini-stroke.
If a woman is taking atomoxetine and experiences any of the side effects listed at the end of this medication guide guide guide to get in the habit of taking it. The risk of developing such side effects may be increased by taking the medication with food.
If a woman is taking atomoxetine and experiences any of the side effects listed at the end of this guide to get in the habit of taking it, including headaches, dizziness, nausea, vomiting, and abdominal pain, notify the doctor or pharmacist promptly.
Avoid consumption of alcohol while taking this medication. Avoid use if the following signs of side effects are observed: nausea, vomiting, headache, shaking, no coordination, fast heartbeat.
Precautions.Do not take this medication if you have had an allergic reaction to atomoxetine, any of the ingredients in the drug, or any of the above. Do not use it if you have a history of heart problems, stroke, blood clots, liver problems, an abnormal electrical activity in the brain, a recent stroke or heart attack, epilepsy, a heart attack within the last six months, a bleeding disorder, blood cancer, asthma, diabetes, kidney problems, severe liver problems, tumour of the lungs, retinitis pigmentosa, epilepsy or migraine, problems with the kidneys, chest pain or irregular heartbeat, or any condition that increases the risk of cardiovascular disease.
Use this medication for the shortest possible time while taking it. If you experience serious side effects, such as nausea, dizziness, blurred vision, difficulty breathing, or changes in urine production, it is recommended that you contact a doctor immediately.
Patients who are pregnant or may become pregnant should not handle the crushed and chewed tablet. The medication may harm the developing fetus or nursing baby. The medication should not be given to a woman who has previously had a heart attack, stroke, or mini-stroke.
Avoid use if a woman is taking the drug for any length of time. In general, women who are pregnant or may become pregnant should not handle the tablets. The use of the medication is not recommended if the patient is breast-feeding or planning to breast-feed.
Contraindications.Atomoxetine should not be taken if the patient is taking any drug known as MAOIs or serotonin-norepinephrine reuptake inhibitors (SNRIs) such as etodolac, fentanyl, metoprolol, phenelzine, selegiline, and venlafaxine.
Patients who are hypersensitive to the components of the drug, its inactive ingredients, or to any of the other ingredients of this medicine, as well as those using it, may experience some degree of skin reactions including itching, blisters, skin rash, skin rashes, and the like.
The presence of a chemical in the drug may increase the risk of serious side effects. In the event of a serious side effect, notify a doctor immediately.
Atomoxetine Dosage (Strength)Dosage (Strength)Atomoxetine is available as the brand name Adderall (amphetamine/dextran). This medication is also available under the brand name Strattera. Adderall is a medication used to treat major depressive disorder.
Dosage may vary depending on the patient and their particular condition. Usually, a low dose of this medication is given initially. Then, higher doses of this medication are given for a longer duration. Patients should take the medication for as long as their doctor prescribes the dose.
The most common side effects of atomoxetine include; headache; upset stomach; change in appetite; nausea, vomiting, or diarrhea; abdominal pain or swelling; increased sweating; increased appetite; or constipation.
Warning.
[]
Objective: To assess the safety, tolerability, and efficacy of atomoxetine (Strattera) in the treatment of ADHD. Methods: Participants included adult patients who had ADHD who received a combination of methylphenidate (Ritalin) and atomoxetine. All patients were diagnosed with ADHD by a doctor, and were asked about their symptoms and their response to the medication. The study included 662 adult patients with ADHD who were treated with atomoxetine and were followed up for 6 months. The main outcome measure was the change in total ADHD symptoms (TS) and the change in daily symptomatology (DTS) as measured by the International Adult ADHD Severity Scale (IAAS). The efficacy question was whether the change in the T-symptom scores of the patients (T-SRS) and T-DTS was significantly better than the change in the T-SRS, in patients receiving atomoxetine (Strattera). Secondary outcomes were T-SRS, the total ADHD symptoms and the DTS score, and the change in T-SRS as measured by the ADHD Global Assessment Scale (ADHD-GAS). Results: Of the 662 patients included, 155 were treated with atomoxetine and were followed up for 6 months. The mean change in T-SRS and the change in the T-SRS in patients receiving atomoxetine was significantly greater than the change in T-SRS in patients receiving atomoxetine alone. The mean change in T-SRS was significantly better than the change in T-SRS in patients receiving atomoxetine. The mean change in the T-DTS was significantly better than the change in the T-SRS.Objective: To evaluate the efficacy and safety of atomoxetine (Strattera) in the treatment of ADHD. Methods: Of the 155 patients treated with atomoxetine and followed up for 6 months, the patients were followed up for the first year for assessment of the T-SRS and the T-DTS. The mean change in T-SRS and the change in the T-DTS was significantly better than the change in T-SRS in patients receiving atomoxetine alone. The mean change in the T-SRS was significantly better than the change in T-SRS in patients receiving atomoxetine.Efficacy: Atomoxetine, a selective norepinephrine reuptake inhibitor, is approved for the treatment of ADHD and has been shown to have a positive effect on ADHD symptoms. The most common adverse events (AEs) reported were headache, insomnia, nausea, and dizziness. A positive effect on ADHD symptoms was observed with atomoxetine, with higher doses having a higher effect on ADHD symptoms. In addition, atomoxetine was found to improve ADHD symptoms in some patients. However, in some patients the drug does not improve ADHD symptoms. The most common AEs reported were headache and insomnia. The incidence of serious AEs was higher in patients taking atomoxetine. The most common treatment-related AEs were mood disorder (nausea, depression) and insomnia. The most common adverse events reported were headache and insomnia.Dosage: Atomoxetine (Strattera) is usually prescribed once daily, as prescribed by a doctor. For patients with a recent history of ADHD, atomoxetine is usually started at a low dose and increased gradually to a dose that is sufficient to treat ADHD symptoms. The dose of atomoxetine should be gradually increased in order to achieve the desired effect.
Stade de France Pharmacy